医药股随A股同业受捧 药明康德、信达、康方、荣昌及开拓涨近9.5%-24%
中证监重申会严惩操纵市场恶意做空,加上中央汇金扩大ETF增持范围,沪指及深成午后升幅曾扩至逾3%-6%,分别高见2,802及8,471。恒指及国指均突破重越10天及20天线,午后高见16,116及5,459,现报16,107及5,442,急涨597点或近3.9%及236点或4.5%,总成交额960亿元。
内地生物疫苗及医药生物板块均急涨7%-7.6%。本港医药板块也不甘寂寞,尤其是开拓药业(09939.HK)高见1.98元,现报1.87元,急升近24%。荣昌生物(09995.HK)重越10天线,最高见18.36元,现报17.88元,急涨16%;康方生物(09926.HK)重越100天线,报43.1元,急涨近11%。信达生物(01801.HK)重越10天线,现报33.05元,急涨近10%。腾盛博药(02137.HK)高见1.84元,现报1.77元,急涨9.9%。
蓝筹翰森(03692.HK)高见12.84元,现报12.82元,急升9.8%。金斯瑞(01548.HK)高见14.12元,现报13.96元,涨8.9%。君实生物(01877.HK)升逾7%股价曾高见12.36元。
蓝筹药明康德(02359.HK)高见49.95元,现报49.7元,续升9.4%;药明康德A(603259.SH)涨逾7%曾高见51.12元人民币。
凯莱英(06821.HK)重越10天线,高见66.4元,现报65.85元,急升8%;凯莱英A(002821.SZ)升近6%曾高见89.84元民币。
康希诺生物(06185.HK)升7.6%报16.64元;康希诺A(688185.SH)涨逾9%报50.3元人民币。
复星医药(02196.HK)由逾十年低位连升第二天,现报14.04元,续升近6%;复星医药A(600196.SH)涨8.5%报22.99元人民币。
药明合联(02268.HK)、药明生物(02269.HK)、来凯医药-B(02105.HK)、蓝筹国药(01099.HK)、艾美疫苗(06660.HK)、联邦制药(03933.HK)、中生(01177.HK)及石药(01093.HK)升近4%-6.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.